Here are the DEF 14A proxy statements from Polaryx Therapeutics, Inc. (PLYX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PLYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLYX filings page.
Polaryx Therapeutics, Inc. is holding a virtual 2026 annual stockholders’ meeting on September 10, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on July 27, 2026, when 49,845,993 common shares were outstanding, may vote.
Stockholders are asked to elect two Class I directors, Alex Yang and Mitchel Berger, to terms ending at the 2029 meeting, and to ratify Grant Thornton LLP as independent registered public accounting firm for 2026. The board is classified into three staggered classes, and has determined that three directors are independent under Nasdaq rules. A major holder affiliated with Mstone controls 22,833,249 shares, or 45.81% of voting power. The proxy also details executive compensation built largely around restricted stock units, a new 2025 equity incentive plan with share reserves, and several related-party arrangements, including service and licensing agreements with Mstone and Rush University Medical Center.